Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
AstraZeneca (NYSE:AZN) announced that an FDA Oncologic Drugs Advisory Committee (ODAC) voted 7-1 with 1 abstention that TRUQAP (capivasertib) plus abiraterone and ADT has a favorable benefit-risk profile for PTEN-deficient metastatic hormone-sensitive prostate cancer based on CAPItello-281.
CAPItello-281 showed a 19% reduction in risk of radiographic progression or death (HR 0.81; 95% CI 0.66-0.98; P=0.034), with median rPFS 33.2 vs 25.7 months (improvement 7.5 months). Grade ≥3 adverse events occurred in 67% vs 40.4% (comparator); OS data remain immature.
Pinetree Therapeutics announced AstraZeneca (LSE/STO/NYSE: AZN) has exercised its option to obtain an exclusive global license to develop and commercialize PTX-299, a bispecific antibody degrader targeting EGFR.
The option exercise triggers a $25 million option-closing payment to Pinetree and makes AstraZeneca responsible for global development and commercialization; the deal includes future development, regulatory, and commercial milestones plus tiered royalties, with total potential value exceeding $500 million.
AstraZeneca (NYSE:AZN) reported Q1 2026 Total Revenue of $15,288m (CER +8%) and Product Revenue of $15,211m. Core EPS was $2.58 and reported EPS $1.99. Growth was driven by double‑digit Oncology and Rare Disease performance and multiple Phase III positive readouts and approvals.
Guidance for FY 2026 at CER was reconfirmed: mid‑to‑high single‑digit Total Revenue growth and low double‑digit Core EPS growth; Core tax rate 18–22%.
AstraZeneca (NYSE: AZN) announced FDA approval of BREZTRI Aerosphere for maintenance treatment of asthma in patients 12 years and older, marking the first single-inhaler fixed-dose triple therapy approved for this population.
Approval was based on Phase III KALOS and LOGOS (≈4,300 patients) showing significant FEV1 improvement versus ICS/LABA and a rapid onset of action within five minutes; no new safety signals identified. BREZTRI was prescribed to >6.8 million patients globally in 2025.
AstraZeneca (NYSE: AZN) announced FDA approval (April 27, 2026) of SAPHNELO Pen for once-weekly subcutaneous self-administration of anifrolumab for adults with moderate-to-severe systemic lupus erythematosus (SLE) on standard therapy. Approval follows Phase III TULIP-SC, which met its primary endpoint (BICLA at Week 52) and reported safety consistent with IV use.
The autoinjector expands access beyond IV infusion, complements existing approvals in the EU and Japan, and follows an updated agreement to pay Bristol-Myers Squibb a mid-teens US royalty.
AstraZeneca (NYSE:AZN) reported that tozorakimab met the primary endpoint in the Phase III MIRANDA trial, showing a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations in former smokers and the overall population. MIRANDA randomized 1,454 patients and tested tozorakimab 300mg every two weeks versus placebo on top of inhaled standard of care over 52 weeks. Tozorakimab was generally well tolerated with a safety profile consistent with prior trials. Data will be submitted to regulators and presented at a medical meeting.
AstraZeneca (AZN) reported positive interim EMERALD-3 Phase III results on April 2, 2026: IMFINZI (durvalumab) + IMJUDO (tremelimumab-actl) combined with lenvatinib and TACE produced a statistically significant, clinically meaningful improvement in progression-free survival (PFS) versus TACE alone for embolization-eligible unresectable hepatocellular carcinoma.
The combination also showed a trend toward improved overall survival (OS); safety profiles were consistent with known profiles and no new safety findings were reported. Data will be presented at a medical meeting and shared with regulators.
AstraZeneca (NYSE:AZN) reported that tozorakimab met the primary endpoint in both Phase III OBERON and TITANIA trials, reducing the annualized rate of moderate-to-severe COPD exacerbations versus placebo in former smokers and the overall population. Trials randomized 2,306 patients; dosing was 300 mg every four weeks. Tozorakimab was generally well tolerated. Additional Phase III trials PROSPERO (1,713 randomized) and MIRANDA (1,454) are ongoing with results expected in H1 2026.
AstraZeneca (NYSE: AZN) on March 10, 2026 launched the national Get Body Checked Against Cancer public health campaign featuring actor Joshua Jackson and the Philadelphia Flyers mascot Gritty.
The campaign promotes conversations with doctors about cancer risk and screenings, supports Hockey Fights Cancer, and notes a $1.1 million donation to the V Foundation. Visit Getbodychecked.com for resources and screening locations.
AstraZeneca (NYSE:AZN) and Daiichi Sankyo announced the FDA has accepted the sBLA for ENHERTU as post‑neoadjuvant treatment for adults with HER2‑positive early breast cancer and granted Priority Review. The Prescription Drug User Fee Act action date is anticipated in Q3 2026 and the application is under Project Orbis.
Approval is supported by DESTINY‑Breast05 Phase III data showing a 53% reduction in risk of invasive disease recurrence or death (HR 0.47; 95% CI 0.34–0.66) and three‑year IDFS 92.4% vs 83.7% with T‑DM1. Safety highlights include ILD risk and established warnings.